

(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 10:49AM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

### SWASTHYA WELLNESS PANEL: 1.5 COMPLETE BLOOD COUNT (CBC)

#### **RED BLOOD CELLS (RBCS) COUNT AND INDICES**

HAEMOGLOBIN (HB) by CALORIMETRIC	12.4	gm/dL	12.0 - 16.0
RED BLOOD CELL (RBC) COUNT by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	4.7	Millions/cmm	3.50 - 5.00
PACKED CELL VOLUME (PCV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	39.6	%	37.0 - 50.0
MEAN CORPUSCULAR VOLUME (MCV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	84.2	fL	80.0 - 100.0
MEAN CORPUSCULAR HAEMOGLOBIN (MCH) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	26.4 <sup>L</sup>	pg	27.0 - 34.0
MEAN CORPUSCULAR HEMOGLOBIN CONC. (MCHC) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	31.3 <sup>L</sup>	g/dL	32.0 - 36.0
RED CELL DISTRIBUTION WIDTH (RDW-CV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	13.9	%	11.00 - 16.00
RED CELL DISTRIBUTION WIDTH (RDW-SD) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	43.7	fL	35.0 - 56.0
MENTZERS INDEX by CALCULATED	17.91	RATIO	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING INDEX by CALCULATED	24.92	RATIO	BETA THALASSEMIA TRAIT:<= 65.0 IRON DEFICIENCY ANEMIA: > 65.0
WHITE BLOOD CELLS (WBCS)			
TOTAL LEUCOCYTE COUNT (TLC) by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	5920	/cmm	4000 - 11000
NUCLEATED RED BLOOD CELLS (nRBCS) by AUTOMATED 6 PART HEMATOLOGY ANALYZER	NIL		0.00 - 20.00
NUCLEATED RED BLOOD CELLS (nRBCS) %	NIL	%	< 10 %



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS MD (PATHOLOGY)



by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER



(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 10:49AM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval
DIFFERENTIAL LEUCOCYTE COUNT (DLC)			
NEUTROPHILS	56	%	50 - 70
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY LYMPHOCYTES	36	%	20 - 40
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY EOSINOPHILS	2	%	1 - 6
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY MONOCYTES	6	%	2 - 12
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY BASOPHILS	0	%	0 - 1
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY  ABSOLUTE LEUKOCYTES (WBC) COUNT			
ABSOLUTE NEUTROPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	3315	/cmm	2000 - 7500
ABSOLUTE LYMPHOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	2131	/cmm	800 - 4900
ABSOLUTE EOSINOPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	118	/cmm	40 - 440
ABSOLUTE MONOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	355	/cmm	80 - 880
ABSOLUTE BASOPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	/cmm	0 - 110
PLATELETS AND OTHER PLATELET PREDICTIVE	MARKERS.		
PLATELET COUNT (PLT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	358000	/cmm	150000 - 450000
PLATELETCRIT (PCT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	0.38 <sup>H</sup>	%	0.10 - 0.36
MEAN PLATELET VOLUME (MPV) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	11	fL	6.50 - 12.0
PLATELET LARGE CELL COUNT (P-LCC) by hydro dynamic focusing, electrical impedence	110000 <sup>H</sup>	/cmm	30000 - 90000
PLATELET LARGE CELL RATIO (P-LCR) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	30.7	%	11.0 - 45.0
PLATELET DISTRIBUTION WIDTH (PDW)  by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE  NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD	16.4	%	15.0 - 17.0



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana



# KOS Diagnostic Lab (A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

**AGE/ GENDER PATIENT ID** : 1687919 : 29 YRS/FEMALE

**COLLECTED BY** : 012412020015 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM **COLLECTION DATE** BARCODE NO. :01521832 : 02/Dec/2024 10:22AM REPORTING DATE CLIENT CODE. : KOS DIAGNOSTIC LAB : 02/Dec/2024 10:49AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Test Name Value** Unit **Biological Reference interval** 



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 03:20PM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

#### **GLYCOSYLATED HAEMOGLOBIN (HBA1C)**

GLYCOSYLATED HAEMOGLOBIN (HbA1c): 5.3 % 4.0 - 6.4

WHOLE BLOOD

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

ESTIMATED AVERAGE PLASMA GLUCOSE 105.41 mg/dL 60.00 - 140.00

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

#### **INTERPRETATION:**

AS PER AMERICAN DIABETES ASSOCIATION (ADA):				
REFERENCE GROUP	GLYCOSYLATED HEMOGLOGIB (HBAIC) in %			
Non diabetic Adults >= 18 years	<5.7			
At Risk (Prediabetes)	5.7 – 6.4 >= 6.5			
Diagnosing Diabetes				
	Age > 19 Years			
	Goals of Therapy:	< 7.0		
Therapeutic goals for glycemic control	Actions Suggested:	>8.0		
	Age < 19 Years			
	Goal of therapy:	<7.5		

#### COMMENTS:

- 1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.

  2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.
- 3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.
- 4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.
- 6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia,increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** REG. NO./LAB NO. :012412020015

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 02/Dec/2024 11:06AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Value** Unit **Biological Reference interval Test Name** 

#### **ERYTHROCYTE SEDIMENTATION RATE (ESR)**

ERYTHROCYTE SEDIMENTATION RATE (ESR)

mm/1st hr 21<sup>H</sup>

by RED CELL AGGREGATION BY CAPILLARY PHOTOMETRY

#### INTERPRETATION:

- 1. ESR is a non-specific test because an elevated result often indicates the presence of inflammation associated with infection, cancer and auto-immune disease, but does not tell the health practitioner exactly where the inflammation is in the body or what is causing it.

  2. An ESR can be affected by other conditions besides inflammation. For this reason, the ESR is typically used in conjunction with other test such
- as C-reactive protein
- 3. This test may also be used to monitor disease activity and response to therapy in both of the above diseases as well as some others, such as systemic lupus erythematosus
  CONDITION WITH LOW ESR

A low ESR can be seen with conditions that inhibit the normal sedimentation of red blood cells, such as a high red blood cell count (polycythaemia), significantly high white blood cell count (leucocytosis), and some protein abnormalities. Some changes in red cell shape (such as sickle cells in sickle cell anaemia) also lower the ESR.

NOTE:

- ESR and C reactive protein (C-RP) are both markers of inflammation.
   Generally, ESR does not change as rapidly as does CRP, either at the start of inflammation or as it resolves.
   CRP is not affected by as many other factors as is ESR, making it a better marker of inflammation.
   If the ESR is elevated, it is typically a result of two types of proteins, globulins or fibrinogen.
   Women tend to have a higher ESR, and menstruation and pregnancy can cause temporary elevations.
   Progs such as doubtern mathyldona, oral contracentives, popicillamino procesingmide, the only viling, and vitality in the orange of the contracentives.

- 6. Drugs such as dextran, methyldopa, oral contraceptives, penicillamine procainamide, theophylline, and vitamin A can increase ESR, while aspirin, cortisone, and quinine may decrease it



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** REG. NO./LAB NO. :012412020015

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 02/Dec/2024 11:04AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Value** Unit **Biological Reference interval Test Name** 

#### **CLINICAL CHEMISTRY/BIOCHEMISTRY GLUCOSE FASTING (F)**

GLUCOSE FASTING (F): PLASMA 83.39 NORMAL: < 100.0 mg/dL

by GLUCOSE OXIDASE - PEROXIDASE (GOD-POD) PREDIABETIC: 100.0 - 125.0

DIABETIC: > 0R = 126.0

INTERPRETATION
IN ACCORDANCE WITH AMERICAN DIABETES ASSOCIATION GUIDELINES:

1. A fasting plasma glucose level below 100 mg/dl is considered normal.

2. A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood

test (after consumption of 75 gms of glucose) is recommended for all such patients.

3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 11:49AM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval
	LIPID PROFILE	: BASIC	
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP	205.17 <sup>H</sup>	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)	105.87	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION	61.76	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	140.24 <sup>H</sup>	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	143.41 <sup>H</sup>	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	21.17	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY	534.21	mg/dL	350.00 - 700.00
CHOLESTEROL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	3.32	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

AGE/ GENDER : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** REG. NO./LAB NO. :012412020015

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 02/Dec/2024 11:49AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	2.27	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED. SPECTROPHOTOMETRY	1.71 <sup>L</sup>	RATIO	3.00 - 5.00

#### **INTERPRETATION:**

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 11:49AM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

#### **LIVER FUNCTION TEST (COMPLETE)**

BILIRUBIN TOTAL: SERUM by DIAZOTIZATION, SPECTROPHOTOMETRY	0.45	mg/dL	INFANT: 0.20 - 8 ADULT: 0.00 - 1.
BILIRUBIN DIRECT (CONJUGATED): SERUM by DIAZO MODIFIED, SPECTROPHOTOMETRY	0.11	mg/dL	0.00 - 0.40
BILIRUBIN INDIRECT (UNCONJUGATED): SERUM by CALCULATED, SPECTROPHOTOMETRY	0.34	mg/dL	0.10 - 1.00
SGOT/AST: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	23.9	U/L	7.00 - 45.00
SGPT/ALT: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	32.2	U/L	0.00 - 49.00
AST/ALT RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	0.74	RATIO	0.00 - 46.00
ALKALINE PHOSPHATASE: SERUM by PARA NITROPHENYL PHOSPHATASE BY AMINO METHYL PROPANOL	86.87	U/L	40.0 - 130.0
GAMMA GLUTAMYL TRANSFERASE (GGT): SERUM by SZASZ, SPECTROPHTOMETRY	12.38	U/L	0.00 - 55.0
TOTAL PROTEINS: SERUM by BIURET, SPECTROPHOTOMETRY	6.86	gm/dL	6.20 - 8.00
ALBUMIN: SERUM by BROMOCRESOL GREEN	4.36	gm/dL	3.50 - 5.50
GLOBULIN: SERUM by CALCULATED, SPECTROPHOTOMETRY	2.5	gm/dL	2.30 - 3.50
A: GRATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.74	RATIO	1.00 - 2.00

#### INTERPRETATION

NOTE:- To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range.

**USE**:- Differential diagnosis of diseases of hepatobiliary system and pancreas.

#### INCREASED:

DRUG HEPATOTOXICITY	> 2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5
HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS	> 1.3 (Slightly Increased)



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUĞAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



8.00 .20

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

: 02/Dec/2024 11:49AM

NAME : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

#### **DECREASED:**

1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)

2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

#### PROGNOSTIC SIGNIFICANCE:

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana
KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana
0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** :012412020015 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 02/Dec/2024 11:49AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval
KIDNI	EY FUNCTION TE	ST (COMPLETE)	
UREA: SERUM by urease - glutamate dehydrogenase (gldh)	27.61	mg/dL	10.00 - 50.00
CREATININE: SERUM by ENZYMATIC, SPECTROPHOTOMETERY	0.97	mg/dL	0.40 - 1.20
BLOOD UREA NITROGEN (BUN): SERUM by CALCULATED, SPECTROPHOTOMETRY	12.9	mg/dL	7.0 - 25.0
BLOOD UREA NITROGEN (BUN)/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	13.3	RATIO	10.0 - 20.0
UREA/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	28.46	RATIO	
URIC ACID: SERUM by URICASE - OXIDASE PEROXIDASE	2.95	mg/dL	2.50 - 6.80
CALCIUM: SERUM by ARSENAZO III, SPECTROPHOTOMETRY	10.09	mg/dL	8.50 - 10.60
PHOSPHOROUS: SERUM by PHOSPHOMOLYBDATE, SPECTROPHOTOMETRY	3.16	mg/dL	2.30 - 4.70
ELECTROLYTES			
SODIUM: SERUM by ISE (ION SELECTIVE ELECTRODE)	137.8	mmol/L	135.0 - 150.0
POTASSIUM: SERUM by ISE (ION SELECTIVE ELECTRODE)	3.89	mmol/L	3.50 - 5.00
CHLORIDE: SERUM by ISE (ION SELECTIVE ELECTRODE)	103.35	mmol/L	90.0 - 110.0
ESTIMATED GLOMERULAR FILTERATION RATE			

ESTIMATED GLOMERULAR FILTERATION RATE 81.1

(eGFR): SERUM by CALCULATED **INTERPRETATION:** 

To differentiate between pre- and post renal azotemia.

#### INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

- 1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.
- 2. Catabolic states with increased tissue breakdown.
- 3. GI haemorrhage.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

AGE/ GENDER : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** REG. NO./LAB NO. :012412020015

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 02/Dec/2024 11:49AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Test Name** Value Unit **Biological Reference interval** 

4. High protein intake.

5. Impaired renal function plus

6. Excess protein intake or production or tissue breakdown (e.g. infection, GI bleeding, thyrotoxicosis, Cushing's syndrome, high protein diet, burns, surgery, cachexia, high fever).

7. Urine reabsorption (e.g. ureter colostomy)

8. Reduced muscle mass (subnormal creatinine production)

9. Certain drugs (e.g. tetracycline, glucocorticoids)

#### INCREASED RATIO (>20:1) WITH ELEVATED CREATININE LEVELS:

- 1. Postrenal azotemia (BUN rises disproportionately more than creatinine) (e.g. obstructive uropathy).
- 2. Prerenal azotemia superimposed on renal disease.

#### DECREASED RATIO (<10:1) WITH DECREASED BUN:

- 1. Acute tubular necrosis.
- 2. Low protein diet and starvation.
- 3. Severe liver disease.
- 4. Other causes of decreased urea synthesis.
- 5. Repeated dialysis (urea rather than creatinine diffuses out of extracellular fluid).
- 6. Inherited hyperammonemias (urea is virtually absent in blood).
- 7. SIADH (syndrome of inappropiate antidiuretic harmone) due to tubular secretion of urea.
- 8. Pregnancy.

#### **DECREASED RATIO (<10:1) WITH INCREASED CREATININE:**

- 1. Phenacimide therapy (accelerates conversion of creatine to creatinine).
- 2. Rhabdomyolysis (releases muscle creatinine).
- 3. Muscular patients who develop renal failure.

#### **INAPPROPIATE RATIO:**

1. Diabetic ketoacidosis (acetoacetate causes false increase in creatinine with certain methodologies, resulting in normal ratio when dehydration should produce an increased BUN/creatinine ratio).

2. Cephalosporin therapy (interferes with creatinine measurement). **ESTIMATED GLOMERULAR FILTERATION RATE**:

CONTROL OF CONTROL OF TAXABLE CO				
CKD STAGE	DESCRIPTION	GFR ( mL/min/1.73m2 )	ASSOCIATED FINDINGS	
G1	Normal kidney function	>90	No proteinuria	
G2	Kidney damage with normal or high GFR	>90	Presence of Protein , Albumin or cast in urine	
G3a	Mild decrease in GFR	60 -89		
G3b	Moderate decrease in GFR	30-59		
G4	Severe decrease in GFR	15-29		
G5	Kidney failure	<15		



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



### **KOS Diagnostic Lab** (A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

AGE/ GENDER : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY REG. NO./LAB NO. :012412020015

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 02/Dec/2024 11:49AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Test Name** Value Unit **Biological Reference interval** 

#### COMMENTS:

1. Estimated Glomerular filtration rate (eGFR) is the sum of filtration rates in all functioning nephrons and so an estimation of the GFR provides a measure of functioning nephrons of the kidney.

2. eGFR calculated using the 2009 CKD-EPI creatinine equation and GFR category reported as per KDIGO guideline 2012

3. In patients, with eGFR creating between 45-59 ml/min/1.73 m2 (G3) and without any marker of Kidney damage, It is recommended to measure

4. eGFR category G1 OR G2 does not fullfill the criteria for CKD, in the absence of evidence of Kidney Damage
5. In a suspected case of Acute Kidney Injury (AKI), measurement of eGFR should be done after 48-96 hours of any Intervention or procedure
6. eGFR calculated by Serum Creatinine may be less accurate due to certain factors like Race, Muscle Mass, Diet, Certain Drugs. In such cases, eGFR should be calculated using Serum Cystatin C
7. A decrease in eGFR implies either progressive renal disease, or a reversible process causing decreased nephron function (eg, severe dehydration).

KDIGO guideline, 2012 recommends Chronic Kidney Disease (CKD) should be classified based on cause, eGFR category and Albuminuria (ACR) category. GFR & ACR category combined together reflect risk of progression and helps Clinician to identify the individual who are progressing at more rapid rate than anticipated



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** :012412020015 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 02/Dec/2024 11:53AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval
	IRON PROFI	LE	
IRON: SERUM by FERROZINE, SPECTROPHOTOMETRY	50.91	μg/dL	37.0 - 145.0
UNSATURATED IRON BINDING CAPACITY (UIBC) :SERUM by FERROZINE, SPECTROPHOTOMETERY	236.59	μg/dL	150.0 - 336.0
TOTAL IRON BINDING CAPACITY (TIBC) :SERUM by SPECTROPHOTOMETERY	287.5	μg/dL	230 - 430
%TRANSFERRIN SATURATION: SERUM by CALCULATED, SPECTROPHOTOMETERY (FERENE)	17.71	%	15.0 - 50.0
TRANSFERRIN: SERUM by SPECTROPHOTOMETERY (FERENE)	204.13	mg/dL	200.0 - 350.0

#### INTERPRETATION:-

NTERI REPATION.				
VARIABLES	ANEMIA OF CHRONIC DISEASE	IRON DEFICIENCY ANEMIA	THALASSEMIA α/β TRAIT	
SERUM IRON:	Normal to Reduced	Reduced	Normal	
TOTAL IRON BINDING CAPACITY:	Decreased	Increased	Normal	
% TRANSFERRIN SATURATION:	Decreased	Decreased < 12-15 %	Normal	
SERUM FERRITIN:	Normal to Increased	Decreased	Normal or Increased	

#### IRON:

1. Serum iron studies is recommended for differential diagnosis of microcytic hypochromic anemia.i.e iron deficiency anemia, zinc deficiency anemia, anemia of chronic disease and thalassemia syndromes.

2. It is essential to isolate iron deficiency anemia from Beta thalassemia syndromes because during iron replacement which is therapeutic for iron deficiency anemia, is severely contra-indicated in Thalassemia.

TOTAL IRON BINDING CAPACITY (TIBC):

1. It is a direct meaning in the bone marrow.

% TRANSFERRIN SATURATION:

1.Occurs in idiopathic hemochromatosis and transfusional hemosiderosis where no unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of transferrin.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

: 02/Dec/2024 11:53AM

**NAME** : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** REG. NO./LAB NO. :012412020015

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM

: KOS DIAGNOSTIC LAB **CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Value** Unit **Biological Reference interval Test Name** 

REPORTING DATE

#### **ENDOCRINOLOGY**

#### THYROID FUNCTION TEST: TOTAL

TRIIODOTHYRONINE (T3): SERUM ng/mL 0.35 - 1.931.184

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

THYROXINE (T4): SERUM μgm/dL 9.38 4.87 - 12.60

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

THYROID STIMULATING HORMONE (TSH): SERUM 2.466 μIU/mL 0.35 - 5.50

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

3rd GENERATION, ULTRASENSITIVE

#### INTERPRETATION:

CLIENT CODE.

TSH levels are subject to circadian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50%. Hence time of the day has influence on the measured serum TSH concentrations. TSH stimulates the production and secretion of the metabolically active hormones, thyroxine (T4) and triiodothyronine (T3). Failure at any level of regulation of the hypothalamic-pituitary-thyroid axis will result in either underproduction (hypothyroidism) or overproduction(hyperthyroidism) of T4 and/or T3.

CLINICAL CONDITION	Т3	T4	TSH
Primary Hypothyroidism:	Reduced	Reduced	Increased (Significantly)
Subclinical Hypothyroidism:	Normal or Low Normal	Normal or Low Normal	High
Primary Hyperthyroidism:	Increased	Increased	Reduced (at times undetectable)
Subclinical Hyperthyroidism:	Normal or High Normal	Normal or High Normal	Reduced

#### LIMITATIONS:-

- 1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG), and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests
- 2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs
- 3. Serum T4 levels in neonates and infants are higher than values in the normal adult, due to the increased concentration of TBG in neonate serum.
- 4. TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy.

TRIIODOTH	RONINE (T3)	THYROXINE (T4)		THYROID STIMULATING HORMONE (TSH)	
Age	Refferance Range (ng/mL)	Age	Refferance Range (µg/dL)	Age	Reference Range ( μΙU/mL)
0 - 7 Days	0.20 - 2.65	0 - 7 Days	5.90 - 18.58	0 - 7 Days	2.43 - 24.3
7 Days - 3 Months	0.36 - 2.59	7 Days - 3 Months	6.39 - 17.66	7 Days - 3 Months	0.58 - 11.00
3 - 6 Months	0.51 - 2.52	3 - 6 Months	6.75 – 17.04	3 Days – 6 Months	0.70 - 8.40
6 - 12 Months	0.74 - 2.40	6 - 12 Months	7.10 – 16.16	6 – 12 Months	0.70 - 7.00



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

AGE/ GENDER : 29 YRS/FEMALE PATIENT ID : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 11:53AM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name			Value	Unit	t	Biological Reference interval
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50	
11- 19 Years	0.35 - 1.93	11 - 19 Years	4.87- 13.20	11 – 19 Years	0.50 - 5.50	
> 20 years (Adults)	0.35 - 1.93	> 20 Years (Adults)	4.87 - 12.60	> 20 Years (Adults)	0.35-5.50	
	RECOM	MENDATIONS OF TSH LI	VELS DURING PREC	NANCY ( μIU/mL)		
	1st Trimester			0.10 - 2.50		
	2nd Trimester		0.20 – 3.00			
	3rd Trimester			0.30 - 4.10		

#### **INCREASED TSH LEVELS:**

- 1. Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.
- 2. Hypothyroid patients receiving insufficient thyroid replacement therapy.
- 3. Hashimotos thyroiditis
- 4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.
- 5. Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

#### **DECREASED TSH LEVELS:**

- 1.Toxic multi-nodular goiter & Thyroiditis.
- 2. Over replacement of thyroid hormone in treatment of hypothyroidism.
- 3. Autonomously functioning Thyroid adenoma
- 4. Secondary pituitary or hypothalamic hypothyroidism
- 5. Acute psychiatric illness
- 6. Severe dehydration.
- 7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.

8. Pregnancy: 1st and 2nd Trimester



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** REG. NO./LAB NO. :012412020015

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 02/Dec/2024 12:00PM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Value** Unit **Biological Reference interval Test Name** 

### IMMUNOPATHOLOGY/SEROLOGY **HEPATITIS C VIRUS (HCV) ANTIBODY: TOTAL**

HEPATITIS C ANTIBODY (HCV) TOTAL: SERUM

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

S/CO

NEGATIVE: < 1.00 POSITIVE: > 1.00

HEPATITIS C ANTIBODY (HCV) TOTAL

**NON - REACTIVE** 

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY) INITEDDDETATION:

INTERFRETATION.	
RESULT (INDEX)	REMARKS
< 1.00	NON - REACTIVE/NOT - DETECTED
> =1.00	REACTIVE/ASYMPTOMATIC/INFECTIVE STATE/CARRIER STATE.

Hepatitis C (HCV) is an RNA virus of Favivirus group transmitted via blood transfusions, transplantation, injection drug abusers, accidental needle punctures in healthcare workers, dialysis patients and rarely from mother to infant. 10 % of new cases show sexual transmission. As compared to HAV & HBV, chronic infection with HCV occurs in 85 % of infected individuals. In high risk population, the predictive value of Anti HCV for HCV infection is > 99% whereas in low risk populations it is only 25 %.

- 1. Indicator of past or present infection, but does not differentiate between Acute/ Chronic/Resolved Infection.
- 2. Routine screening of low and high prevelance population including blood donors.
- NOTF:
- 1. False positive results are seen in Auto-immune disease, Rheumatoid Factor, HYpergammaglobulinemia, Paraproteinemia, Passive antibody transfer, Anti-idiotypes and Anti-superoxide dismutase.
- 2. False negative results are seen in early Acute infection, Immunosuppression and Immuno—incompetence.

3. HCV-RNA PCR recommended in all reactive results to differentiate between past and present infection.



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

:02/Dec/2024 12:00PM

**NAME** : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** REG. NO./LAB NO. :012412020015

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM

: KOS DIAGNOSTIC LAB **CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Test Name Value** Unit **Biological Reference interval** 

REPORTING DATE

#### ANTI HUMAN IMMUNODEFICIENCY VIRUS (HIV) DUO ULTRA WITH (P-24 ANTIGEN DETECTION)

HIV 1/2 AND P24 ANTIGEN: SERUM S/CO NEGATIVE: < 1.00 by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY) POSITIVE: > 1.00

HIV 1/2 AND P24 ANTIGEN RESULT **NON - REACTIVE** 

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

INTERPRETATION:-

CLIENT CODE.

INTERI RETATION.	
RESULT (INDEX)	REMARKS
< 1.00	NON - REACTIVE
> = 1.00	PROVISIONALLY REACTIVE

Non-Reactive result implies that antibodies to HIV 1/2 have not been detected in the sample. This menas that patient has either not been exposed to HIV 1/2 infection or the sample has been tested during the "window phase" i.e. before the development of detectable levels of antibodies. Hence a Non Reactive result does not exclude the possibility of exposure or infection with HIV 1/2. RECOMMENDATIONS:

1. Results to be clinically correlated

2. Rarely falsenegativity/positivity may occur.



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

AGE/ GENDER : 29 YRS/FEMALE PATIENT ID : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 11:53AM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

#### HEPATITIS B SURFACE ANTIGEN (HBsAg) ULTRA

HEPATITIS B SURFACE ANTIGEN (HBsAg):

0.04 S

NEGATIVE: < 1.0 POSITIVE: > 1.0

SERUM

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

HEPATITIS B SURFACE ANTIGEN (HBsAg)

NON REACTIVE

**RESULT** 

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

#### INTERPRETATION:

RESULT IN INDEX VALUE	REMARKS
< 1.30	NEGATIVE (-ve)
>=1.30	POSITIVE (+ve)

Hepatitis B Virus (HBV) is a member of the Hepadna virus family causing infection of the liver with extremely variable clinical features. Hepatitis B is transmitted primarily by body fluids especially serum and also spread effectively sexually and from mother to baby. In most individuals HBV hepatitis is self limiting, but 1-2 % normal adolescent and adults develop Chronic Hepatitis. Frequency of chronic HBV infection is 5-10% in immunocompromised patients and 80 % neonates. The initial serological marker of acute infection is HBsAg which typically appears 2-3 months after infection and disappears 12-20 weeks after onset of symtoms. Persistence of HBsAg for more than 6 months indicates carrier state or Chronic Liver disease.



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)









Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra

MD (Pathology)

CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 10:56AM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

**VDRL** 

VDRL NON REACTIVE NON REACTIVE

by IMMUNOCHROMATOGRAPHY

#### **INTERPRETATION:**

1. Does not become positive until 7 - 10 days after appearance of chancre.

2. High titer (>1:16) - active disease.

3.Low titer (<1:8) - biological falsepositive test in 90% cases or due to late or late latent syphillis.

4.Treatment of primary syphillis causes progressive decline tonegative VDRL within 2 years.

5. Rising titer (4X) indicates relapse, reinfection, or treatment failure and need for retreatment.

6. May benonreactive in early primary, late latent, and late syphillis (approx. 25% ofcases).

7. Reactive and weakly reactive tests should always be confirmed with FTA-ABS (fluorescent treponemal antibody absorption test).

#### SHORTTERM FALSE POSITIVE TEST RESULTS (<6 MONTHS DURATION) MAY OCCURIN:

1. Acute viral illnesses (e.g., hepatitis, measles, infectious mononucleosis)

2.M. pneumoniae; Chlamydia; Malaria infection.

3. Some immunizations

4.Pregnancy (rare)

#### LONGTERM FALSE POSITIVE TEST RESULTS (>6 MONTHS DURATION) MAY OCCUR IN:

- 1. Serious underlying disease e.g., collagen vascular diseases, leprosy, malignancy.
- 2.Intravenous drug users.
- 3. Rheumatoid arthritis, thyroiditis, AIDS, Sjogren's syndrome.
- 4.<10 % of patients older thanage 70 years.
- 5. Patients taking some anti-hypertensive drugs.



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)









Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

**COLLECTED BY** REG. NO./LAB NO. :012412020015

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 10:03 AM BARCODE NO. :01521832 **COLLECTION DATE** : 02/Dec/2024 10:22AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 02/Dec/2024 01:45PM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Value** Unit **Biological Reference interval Test Name** 

#### **VITAMINS**

#### VITAMIN D/25 HYDROXY VITAMIN D3

VITAMIN D (25-HYDROXY VITAMIN D3): SERUM ng/mL DEFICIENCY: < 20.0 18.57<sup>L</sup>

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY) INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0

**TOXICITY:** > 100.0

**INTERPRETATION:** 

DEFICIENT:	< 20	ng/mL
INSUFFICIENT:	21 - 29	ng/mL
PREFFERED RANGE:	30 - 100	ng/mL
INTOXICATION:	> 100	ng/mL

- 1. Vitamin D compounds are derived from dietary ergocalciferol (from plants, Vitamin D2), or cholecalciferol (from animals, Vitamin D3), or by conversion of 7- dihydrocholecalciferol to Vitamin D3 in the skin upon Ultraviolet exposure.

  2.25-OH--Vitamin D represents the main body resevoir and transport form of Vitamin D and transport form of Vitamin D, being stored in adipose
- tissue and tightly bound by a transport protein while in circulation.
- 3. Vitamin D plays a primary role in the maintenance of calcium homeostatis. It promotes calcium absorption, renal calcium absorption and phosphate reabsorption, skeletal calcium deposition, calcium mobilization, mainly regulated by parathyroid harmone (PTH).

  4. Severe deficiency may lead to failure to mineralize newly formed osteoid in bone, resulting in rickets in children and osteomalacia in adults.
- DECREASED:
- 1.Lack of sunshine exposure.
- 2.Inadequate intake, malabsorption (celiac disease)
- 3. Depressed Hepatic Vitamin D 25- hydroxylase activity
- 4. Secondary to advanced Liver disease
- 5. Osteoporosis and Secondary Hyperparathroidism (Mild to Moderate deficiency)
- 6.Enzyme Inducing drugs: anti-epileptic drugs like phenytoin, phenobarbital and carbamazepine, that increases Vitamin D metabolism. INCREASED:
- 1. Hypervitaminosis D is Rare, and is seen only after prolonged exposure to extremely high doses of Vitamin D. When it occurs, it can result in severe hypercalcemia and hyperphophatemia.

CAUTION: Replacement therapy in deficient individuals must be monitored by periodic assessment of Vitamin D levels in order to prevent hypervitaminosis D

NOTE:-Dark coloured individuals as compare to whites, is at higher risk of developing Vitamin D deficiency due to excess of melanin pigment which interefere with Vitamin D absorption.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 12:04PM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

#### **VITAMIN B12/COBALAMIN**

VITAMIN B12/COBALAMIN: SERUM 231 pg/mL 190.0 - 890.0

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

#### INTERPRETATION:-

INCREASED VITAMIN B12	DECREASED VITAMIN B12
1.Ingestion of Vitamin C	1.Pregnancy
2.Ingestion of Estrogen	2.DRUGS:Aspirin, Anti-convulsants, Colchicine
3.Ingestion of Vitamin A	3.Ethanol Igestion
4.Hepatocellular injury	4. Contraceptive Harmones
5.Myeloproliferative disorder	5.Haemodialysis
6.Uremia	6. Multiple Myeloma

- 1. Vitamin B12 (cobalamin) is necessary for hematopoiesis and normal neuronal function.
- 2.In humans, it is obtained only from animal proteins and requires intrinsic factor (IF) for absorption.
- 3. The body uses its vitamin B12 stores very economically, reabsorbing vitamin B12 from the ileum and returning it to the liver; very little is excreted.
- 4.Vitamin B12 deficiency may be due to lack of IF secretion by gastric mucosa (eg. gastrectomy, gastric atrophy) or intestinal malabsorption (eg, ileal resection, small intestinal diseases).
- 5.Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of proprioception, poor coordination, and affective behavioral changes. These manifestations may occur in any combination; many patients have the neurologic defects without macrocytic anemia.
- 6.Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states.
- 7.Follow-up testing for antibodies to intrinsic factor (IF) is recommended to identify this potential cause of vitamin B12 malabsorption.

  NOTE:A normal serum concentration of vitamin B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for vitamin B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum vitamin B12 concentrations are normal.



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana



(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

AGE/ GENDER : 29 YRS/FEMALE PATIENT ID : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:31 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:40AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 11:53AM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

#### **TUMOUR MARKER**

#### **CANCER ANTIGEN 19.9 (CA 19.9): PANCREATIC CANCER MARKER**

CANCER ANTIGEN (CA) -19.9: SERUM by CMIA (CHEMILUMINESCENCE MICROPARTICLE IMMUNOASSAY)

21.963

U/mL

0.00 - 41.0

#### **INTERPRETATION:**

- 1.CA 19.9 isolated originally from colon cancer cell line has greatest utility in detecting pancreatic cancers and hence is the most useful circulating tumour marker for evaluating chronic pancreatic disorders.
- 2. The specificity and positive predictive value for cancers increase with higher CA 19.9 values.
- 3. Tumour size and histological grade affect the values, being higher in tumors > 3cms in diameter and in differentiated tumors.
- 4.High levels suggest tumour is unresectable. Used in conjunction with CT scan and other imaging modalities to decide about tumor resection. 5.Useful in predicting survival and recurrence after surgery. A persistent elevation following surgery may be indicative of occult metastasis or recurrence of disease.

#### **INCREASED LEVELS ARE SEEN IN:**

- 1.Pancreatic Cancer
- 2...Cancers of bile duct, stomach, colon and oesophagus
- 3. Some non-gastrointestinal cancers
- 4.Hepatomas
- 5.Non-malignant conditions like hepatitis, cirrhosis, acute cholangitis pancreatitis and cystic fibrosis.

#### NOTE

- 1.CA 19.9 assay should be used as an adjunct with other diagnostic information in the management of pancreatic cancer.
- 2. The results obtained with different analytical techniques and different equipments cannot be used interchangeably due to difference in assay methods and reagent specificity.
- 3. In course of monitoring, the assay method preferably should not be changed



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

AGE/ GENDER : 29 YRS/FEMALE PATIENT ID : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 11:10AM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

# CLINICAL PATHOLOGY URINE ROUTINE & MICROSCOPIC EXAMINATION

#### **PHYSICAL EXAMINATION**

QUANTITY RECIEVED 10 ml

COLOUR PALE YELLOW PALE YELLOW

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

TRANSPARANCY CLEAR CLEAR

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

SPECIFIC GRAVITY

1.02

1.002 - 1.030

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

**CHEMICAL EXAMINATION** 

REACTION ACIDIC by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

PROTEIN Negative NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

SUGAR Negative NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY
pH 6.5 5.0 - 7.5

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

BILIRUBIN Negative NEGATIVE (-ve) by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

NITRITE Negative NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY.

UROBILINOGEN Normal EU/dL 0.2 - 1.0

KETONE BODIES Negative NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

BLOOD Negative NEGATIVE (-ve)

ASCORBIC ACID NEGATIVE (-ve) NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

MICROSCOPIC EXAMINATION

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

RED BLOOD CELLS (RBCs) NEGATIVE (-ve) /HPF 0 - 3



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)





(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mrs. RAJVEER KAUR

**AGE/ GENDER** : 29 YRS/FEMALE **PATIENT ID** : 1687919

COLLECTED BY : REG. NO./LAB NO. : 012412020015

 REFERRED BY
 : 02/Dec/2024 10:03 AM

 BARCODE NO.
 : 01521832
 COLLECTION DATE
 : 02/Dec/2024 10:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 02/Dec/2024 11:10AM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
PUS CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	1-3	/HPF	0 - 5
EPITHELIAL CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	2-4	/HPF	ABSENT
CRYSTALS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
CASTS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
BACTERIA by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
OTHERS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
TRICHOMONAS VAGINALIS (PROTOZOA) by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	ABSENT		ABSENT

\*\*\* End Of Report \*\*\*



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

